Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females
- 149 Downloads
To evaluate the effect of central precocious puberty (CPP) and its treatment with gonadotropin-releasing hormone (GnRH) analogues on final height and peak bone mass (PBM), we measured lumbar bone mineral density (BMD) in 23 girls at final height. Patients were distributed in two groups. Group 1: 14 patients with progressive CPP were treated with GnRH analogues; seven patients received buserelin (1600 μg/daily), subsequently switched to depot triptorelin (60 μg/kg/26–28 days); seven patients were treated with depot triptorelin (60 μg/kg/26–28 days); mean age of treatment was 6.2 years (range 2.7–7.8 years); the treatment was discontinued at the mean age of 10.1 years (range 8.7–11.3 years); final height was reached at the mean age 13.4 years (range 12.0–14.9 years). Group 2: 9 patients (mean age 6.5 years, range 4.8–7.7 years) with a slowly progressing variant of CPP were followed without treatment; final height was reached at the mean age 13.6 years (range 12.5–14.8 years). Lumbar BMD (L2–L4 by dual energy X-ray absorptiometry) was measured in all patients at final height. In group 1, final height (158.9 ± 5.4 cm) was significantly greater than the pre-treatment predicted height (153.5 ± 7.2 cm, P < 0.001), but significantly lower than mid-parental height (163.2 ± 6.2 cm, P < 0.005). Subdividing the girls of group 1 according to the bone age at discontinuation of therapy (i.e. ≤11.5 years, n = 5, or ≥12.0 years, n = 9), the former patients had a final height significantly higher than the latter (163.7 ± 3.9 cm vs 156.5 ± 4.6 cm, P < 0.02). In group 2, final height (161.8 ± 4.6 cm) was similar to the pre-treatment predicted height (163.1 ± 6.2 cm, P = NS) and was not significantly different from mid-parental height (161.0 ± 5.9 cm). BMD values (group 1: 1.11 ± 0.14 g/cm2, group 2: 1.22 ± 0.08 g/cm2) were not significantly different from those of a control group (1.18 ± 0.10 g/cm2; n = 20, age 16.3–20.5 years) and the patients’ mothers (group 1: 1.16 ± 0.07 g/cm2, n = 11, age 32.9–45.1 years; group 2: 1.20 ± 0.08 g/cm2, n = 7, age 33.5–46.5 years). In group 1, the girls who stopped therapy at a bone age ≤11.5 years had significantly higher BMD (1.22 ± 0.10 g/cm2) compared to those who discontinued therapy at a bone age ≥12.0 years (1.04 ± 0.12 g/ cm2, P < 0.05).
In girls with progressive CPP, long-term treatment with GnRH analogues improves final height. A subset of patients with CPP does not require treatment because good statural outcome (slowly progressing variant). In CPP, the abnormal onset of puberty and the long-term GnRH analogue treatment do not impair the achievement of PBM. In GnRH treated patients, the discontinuation of therapy at an appropriate bone age for pubertal onset may improve both final height and PBM.
Key wordsBone mineral density Central precocious puberty Final height Gn-RH analogue treatment Peak bone mass
bone mineral density
central precocious puberty
gonadotropin releasing hormone
peak bone mass
Unable to display preview. Download preview PDF.
- 3.Bayley N, Pinneau SR (1952) Tables for predicting adult height from skeletal age: revised for use with the Greulich and Pyle standards. J Pediatr 40:432–441Google Scholar
- 6.Dawood MY (1994) Hormonal therapies for endometriosis: implications for bone metabolism. Acta Obstet Gynecol [Suppl] 159:22–34Google Scholar
- 10.Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of the hand and wrist, 2nd end. Stanford University Press, StanfordGoogle Scholar
- 20.Oerter KE, Manasco PK, Barnes KM, Jones J, Hill S, Cutler GB Jr (1993) Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty. Acta Paediatr [Suppl] 388:62–68Google Scholar
- 24.Scharia SH, Minne HW, Waibel-Treber S, Schaible A, Lempert UG, Wilster C, et al (1990) Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonist and its relation to pretreatment serum concentrations of 1,25 dihydroxyvitamin D3. J Clin Endocrinol Metab 70:1055–1061CrossRefGoogle Scholar
- 28.Theintz G, Buchs B, Rizzoli R, Sloman D, Clavien H, Sizonenko PC, Bonjour J-PH (1992) Longitudinal monitoring of bone mass accumulation in healthy adolescents: Evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 75:1060–1065PubMedCrossRefGoogle Scholar
- 30.Zachmann M (1992) Assessment of skeletal and sexual maturity: theoretical and practical aspects. Clin Pediatr Endocrinol [Suppl] 3:15–33Google Scholar